New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:45 EDTSNYSanofi Phase II trial of Sanofi JAK2 inhibitor in MF met primary endpoint
Sanofi announced new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis, MF, a hematologic malignancy with unmet medical needs. The data were presented during the 2012 Annual Meeting of the American Society of Hematology in Atlanta, Ga., December 8-11.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use